Multiple brands of methylphenidate hydrochloride products are in shortage or are expected to be in shortage throughout 2025. We have convened a Methylphenidate Medicine Shortage Action Group (MSAG) that includes relevant health professional groups and peak body groups for input to help us manage the shortage.
The Australasian ADHD Professionals Association, a member of our MSAG, has developed guidelines to help clinicians manage the ADHD medicine shortages. The guidelines include information for bridging with methylphenidate IR or switching from methylphenidate to either lisdexamfetamine or dexamfetamine IR during the shortages. Go to: ADHD Medication Shortage Clinical Guidance for Healthcare Professionals to access these resources.
Please go to About the shortage of methylphenidate hydrochloride products for more information about the MSAG and what we have done to mitigate the impact of these shortages.
You can also go to the Medicine Shortage Reports Database - external site (search for ‘methylphenidate’) for the most up-to-date shortage information.